German chemicals firm BASF entered into an agreement on April 26 to invest in an expansion of its production capabilities for bacterial enzymes and other biotechnology products at Sandoz GmbH’s Kundl/Schaftenau campus in Austria.

“The agreement enables us to expand our production footprint for detergent enzymes and further enhance our product portfolio and leading market position in the Home Care and I&I industry,” Dr. Soeren Hildebrandt, senior vice president Home Care, I&I Industrial Formulators Europe, said in a BASF release. “With this step we support our customers to address key market needs such as cleaning products with superior sustainability profiles and new product formats, based on innovative BASF enzyme technology.

BASF said it will examine opportunities to increase its involvement in the Novartis subsidiary’s Kundl/Schaftenau campus. Production is slated to commence at the company’s new site in 2024.

“With the further development into a Life Science park and the settlement of BASF, an important player in the field of biotechnology, we are strengthening the competence and innovation capacity of the area,” said Steffen Lang, head of Novartis Technical Operations and member of the Novartis Executive Committee, in a statement.

Financial terms of the agreement were not disclosed.